KARO PHARMA ANNOUNCES AGREEMENT WITH THE AUSTRIAN PHARMACEUTICAL COMPANY MARINOMED BIOTECH AG

· Karo Pharma AB and the Austrian pharmaceutical company Marinomed Biotech AG today announced a license agreement under which Karo Pharma will market a patented product for common cold & flu symptoms in Sweden, Norway and Finland.
· The product is very well documented with 4 clinical trials in which more than 650 adults and children were included. It has shown good results for the treatment of viral respiratory infections like common cold and flu. The product may be launched already during the first half of 2018, under the name Viruseptin®. 
· The agreement is long term (10 years).
· “We have planned to enter the market for the treatment of cold and flu symptoms since some time. This product enables us to do so in a competitive way. In parallel we will continue to develop T268A as it will further strengthen our product portfolio given its different mode of action” says Anders Lönner Chairman of the Board, Karo Pharma AB

For further information please contact:

Peter Blom, CEO, 070-655 56 98 or peter.blom@karopharma.se

About Karo Pharma
Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.

The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on November 27, 2017 at 08.00 CET. This press release is also available on www.newsroom.cision.com

Forward-looking Statements
This news release contains certain forward-looking statements that are based on uncertainty, as they relate to events and depend on circumstances that will occur in the future and which, by their nature, may have an impact on results of operations and the financial condition of Karo Pharma. Such forward-looking statements reflect our current expectations and are based on the information currently available. Karo Pharma cannot give any assurance as to whether such forward-looking statements will prove to be correct. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. 

Belonging documents

Press release (PDF)